In some good news for women battling locally advanced cervical cancer, new research shows that adding six weeks of chemotherapy to standard treatment cuts the risk of death by 40%.

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation around the world so far to say no to the drug for this condition. It says that it is too expensive for the NHS to fund.

In some good news for women battling locally advanced cervical cancer, new research shows that adding six weeks of chemotherapy to standard treatment cuts the risk of death by 40 percent. “This is the biggest improvement in outcome in this disease in over 20 years,

Cervical cancer affects over 300,000 women worldwide, and the regime has been heralded as “remarkable”— “the biggest gain in survival since the adoption of chemoradiation in 1999.” Those were the words of Dr.